公开(公告)号：US20160022692A1

公开(公告)日：2016-01-28

申请号：US14876589

申请日：2015-10-06

申请人： Infinity Pharmaceuticals, Inc.

发明人： Vito J. PALOMBELLA ,  Jeffery L. KUTOK

IPC分类号： A61K31/5377 ,  A61K31/506 ,  A61K31/519 ,  A61K31/4725 ,  A61K31/52 ,  A61K45/06

CPC分类号： A61K31/5377 ,  A61K31/00 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/501 ,  A61K31/506 ,  A61K31/519 ,  A61K31/52 ,  A61K45/06 ,  G01N33/5047 ,  G01N33/5088 ,  A61K2300/00

摘要： Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating rheumatoid arthritis or asthma.

摘要翻译： 本文提供了包括用于治疗类风湿性关节炎或哮喘的PI3激酶抑制剂的方法，试剂盒和药物组合物。

公开(公告)号：US20150290207A1

公开(公告)日：2015-10-15

申请号：US14661656

申请日：2015-03-18

申请人： Infinity Pharmaceuticals, Inc.

发明人： Jeffery L. KUTOK ,  David G. WINKLER ,  Vito J. PALOMBELLA

IPC分类号： A61K31/5377 ,  A61K31/497 ,  A61K31/4725 ,  A61K31/427 ,  A61K31/337 ,  A61K31/506 ,  A61K39/00 ,  A61K39/395 ,  A61K31/495 ,  A61K31/519 ,  A61K45/06

CPC分类号： A61K31/5377 ,  A61K31/337 ,  A61K31/427 ,  A61K31/4725 ,  A61K31/495 ,  A61K31/497 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K39/0005 ,  A61K39/39533 ,  A61K39/39566 ,  A61K45/06 ,  A61K2039/505 ,  A61K2300/00

摘要： Compounds and pharmaceutical compositions that modulate kinase activity, including PI3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including PI3 kinase activity, are described herein.

公开(公告)号：US20140120083A1

公开(公告)日：2014-05-01

申请号：US13840822

申请日：2013-03-15

申请人： INFINITY PHARMACEUTICALS, INC.

发明人： Howard M. STERN ,  Jeffery L. KUTOK

IPC分类号： A61K31/52 ,  A61K31/5377 ,  A61K31/4725 ,  C07D401/12 ,  A61K45/06 ,  C07D471/04 ,  C07D473/34 ,  C07D473/00 ,  A61K31/519 ,  A61K31/506

CPC分类号： C07D473/34 ,  A61K31/00 ,  A61K45/06 ,  C07D401/12 ,  C07D471/04 ,  C07D473/00

摘要： Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor for treating cancers or hematologic disorders.

摘要翻译： 本文提供了包括用于治疗癌症或血液学障碍的PI3激酶抑制剂的方法，试剂盒和药物组合物。

公开(公告)号：US20240325398A1

公开(公告)日：2024-10-03

申请号：US18385203

申请日：2023-10-30

申请人： Infinity Pharmaceuticals, Inc.

发明人： Jeffery L. KUTOK ,  Howard M. STERN

IPC分类号： A61K31/52 ,  A61K31/573 ,  A61K45/06

CPC分类号： A61K31/52 ,  A61K31/573 ,  A61K45/06

摘要： Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a CDK4/6 inhibitor, 2) an HDAC inhibitor, 3) a MEK inhibitor, 4) a mTOR inhibitor, 5) an AKT inhibitor, 6) a proteasome inhibitor, 7) an immunomodulator, 8) a glucocorticosteroid, 9) a BET inhibitor, 10) an epigenetic inhibitor, 11) a PI3K alpha inhibitor, 12) a topoisomerase inhibitor, or 13) an ERK inhibitor. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer.

公开(公告)号：US20220125794A1

公开(公告)日：2022-04-28

申请号：US17391869

申请日：2021-08-02

申请人： Infinity Pharmaceuticals, Inc.

发明人： Jeffery L. KUTOK ,  Howard M. STERN

IPC分类号： A61K31/52 ,  A61K31/5377 ,  A61K45/06 ,  A61K31/437 ,  A61K31/496

摘要： Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor or a pharmaceutically acceptable form thereof, and a Bcl-2 inhibitor or a pharmaceutically acceptable form thereof. Also provided herein are methods for treating cancer comprising administration the compositions, and uses of the compositions, e.g., for the treatment of cancer.

公开(公告)号：US20240293415A1

公开(公告)日：2024-09-05

申请号：US18644709

申请日：2024-04-24

申请人： Infinity Pharmaceuticals, Inc.

发明人： Jeffery L. KUTOK

IPC分类号： A61K31/52 ,  A61K31/497 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K31/52 ,  A61K31/497 ,  A61K39/39566 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2818 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24

摘要： Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a checkpoint modulator, 2) an XPO1 inhibitor, 3) an anti-CD19 antibody, 4) a TLR agonist, 5) a STING agonist, or 6) a Flt3 ligand, or a combination thereof. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer.

公开(公告)号：US20220241287A1

公开(公告)日：2022-08-04

申请号：US17474282

申请日：2021-09-14

申请人： Infinity Pharmaceuticals, Inc.

发明人： Jeffery L. KUTOK

IPC分类号： A61K31/52 ,  A61P35/00 ,  A61K31/497 ,  A61K39/395 ,  C07K16/28

摘要： Provided herein are pharmaceutical compositions comprising a phosphatidylinositol 3-kinase inhibitor, or pharmaceutically acceptable form thereof, in combination with a second agent, or a pharmaceutically acceptable form thereof, wherein the second agent is chosen from one or more of 1) a checkpoint modulator, 2) an XPO1 inhibitor, 3) an anti-CD19 antibody, 4) a TLR agonist, 5) a STING agonist, or 6) a Flt3 ligand, or a combination thereof. Also provided herein are methods of treatment comprising administration of the compositions, and uses of the compositions, e.g., for treatment of cancer.